CoChat
Sign Up
Cited by 1,438

The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.

Low-grade inflammation as a key mediator of the pathogenesis of osteoarthritis

Robinson, William H., Lepus, Christin M., Wang, Qian, Raghu, Harini, Mao, Rong, Lindstrom, Tamsin M., Sokolove, Jeremy·2016·Nature Reviews Rheumatology
DOI 10.1038/nrrheum.2016.136PMC PMC5500215
Open this paper in CoChat — free account

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/nrrheum.2016.136

Cites

7 of 7 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 7 references

Research works printed but not linked: 197

  1. Lawrence, R. C. et al. Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part II. Arthritis Rheum. 58, 26–35 (2008). · DOI
  2. Felson, D. T. Clinical practice. Osteoarthritis of the knee. N. Engl. J. Med. 354, 841–848 (2006). · DOI
  3. Felson, D. T. et al. Osteoarthritis: new insights. Part 2: treatment approaches. Ann. Intern. Med. 133, 726–737 (2000). · DOI
  4. Blagojevic, M., Jinks, C., Jeffery, A. & Jordan, K. P. Risk factors for onset of osteoarthritis of the knee in older adults: a systematic review and meta-analysis. Osteoarthritis Cartilage 18, 24–33 (2010). · DOI
  5. Zhuo, Q., Yang, W., Chen, J. & Wang, Y. Metabolic syndrome meets osteoarthritis. Nat. Rev. Rheumatol. 8, 729–737 (2012). · DOI
  6. Loeser, R. F., Goldring, S. R., Scanzello, C. R. & Goldring, M. B. Osteoarthritis: a disease of the joint as an organ. Arthritis Rheum. 64, 1697–1707 (2012). · DOI
  7. Sellam, J. & Berenbaum, F. The role of synovitis in pathophysiology and clinical symptoms of osteoarthritis. Nat. Rev. Rheumatol. 6, 625–635 (2010). · DOI · Paper page
  8. Karsdal, M. A. et al. The coupling of bone and cartilage turnover in osteoarthritis: opportunities for bone antiresorptives and anabolics as potential treatments? Ann. Rheum. Dis. 73, 336–348 (2014). · DOI
  9. Goldring, M. B. & Goldring, S. R. Articular cartilage and subchondral bone in the pathogenesis of osteoarthritis. Ann. NY Acad. Sci. 1192, 230–237 (2010). · DOI
  10. Liu-Bryan, R. & Terkeltaub, R. Emerging regulators of the inflammatory process in osteoarthritis. Nat. Rev. Rheumatol. 11, 35–44 (2015). · DOI
  11. Brandt, K. D., Dieppe, P. & Radin, E. L. Commentary: is it useful to subset “primary” osteoarthritis? A critique based on evidence regarding the etiopathogenesis of osteoarthritis. Semin. Arthritis Rheum. 39, 81–95 (2009). · DOI
  12. Guermazi, A. et al. Assessment of synovitis with contrast-enhanced MRI using a whole-joint semiquantitative scoring system in people with, or at high risk of, knee osteoarthritis: the MOST study. Ann. Rheum. Dis. 70, 805–811 (2011). · DOI
  13. Ishijima, M. et al. Relationships between biomarkers of cartilage, bone, synovial metabolism and knee pain provide insights into the origins of pain in early knee osteoarthritis. Arthritis Res. Ther. 13, R22 (2011). · DOI
  14. Pessler, F. et al. The synovitis of “non-inflammatory” orthopaedic arthropathies: a quantitative histological and immunohistochemical analysis. Ann. Rheum. Dis. 67, 1184–1187 (2008). · DOI
  15. Scanzello, C. R. & Goldring, S. R. The role of synovitis in osteoarthritis pathogenesis. Bone 51, 249–257 (2012). · DOI · Paper page
  16. Bondeson, J. et al. The role of synovial macrophages and macrophage-produced mediators in driving inflammatory and destructive responses in osteoarthritis. Arthritis Rheum. 62, 647–657 (2010). · DOI
  17. Nettelbladt, E. & Sundblad, L. Protein patterns in synovial fluid and serum in rheumatoid arthritis and osteoarthritis. Arthritis Rheum. 2, 144–151 (1959). · DOI
  18. Sohn, D. H. et al. Plasma proteins present in osteoarthritic synovial fluid can stimulate cytokine production via Toll-like receptor 4. Arthritis Res. Ther. 14, R7 (2012). · DOI
  19. Gobezie, R. et al. High abundance synovial fluid proteome: distinct profiles in health and osteoarthritis. Arthritis Res. Ther. 9, R36 (2007). · DOI
  20. Pelletier, J. P., Martel-Pelletier, J. & Abramson, S. B. Osteoarthritis, an inflammatory disease: potential implication for the selection of new therapeutic targets. Arthritis Rheum. 44, 1237–1247 (2001). · DOI
  21. Roemer, F. W. et al. Presence of MRI-detected joint effusion and synovitis increases the risk of cartilage loss in knees without osteoarthritis at 30-month follow-up: the MOST study. Ann. Rheum. Dis. 70, 1804–1809 (2011). · DOI
  22. Hill, C. L. et al. Synovitis detected on magnetic resonance imaging and its relation to pain and cartilage loss in knee osteoarthritis. Ann. Rheum. Dis. 66, 1599–1603 (2007). · DOI
  23. Torres, L. et al. The relationship between specific tissue lesions and pain severity in persons with knee osteoarthritis. Osteoarthritis Cartilage 14, 1033–1040 (2006). · DOI
  24. Baker, K. et al. Relation of synovitis to knee pain using contrast-enhanced MRIs. Ann. Rheum. Dis. 69, 1779–1783 (2010). · DOI
  25. Scanzello, C. R. et al. Synovial inflammation in patients undergoing arthroscopic meniscectomy: molecular characterization and relationship to symptoms. Arthritis Rheum. 63, 391–400 (2011). · DOI
  26. Krasnokutsky, S. et al. Quantitative magnetic resonance imaging evidence of synovial proliferation is associated with radiographic severity of knee osteoarthritis. Arthritis Rheum. 63, 2983–2991 (2011). · DOI
  27. Sowers, M., Karvonen-Gutierrez, C. A., Jacobson, J. A., Jiang, Y. & Yosef, M. Associations of anatomical measures from MRI with radiographically defined knee osteoarthritis score, pain, and physical functioning. J. Bone Joint Surg. Am. 93, 241–251 (2011). · DOI
  28. Ayral, X., Pickering, E. H., Woodworth, T. G., Mackillop, N. & Dougados, M. Synovitis: a potential predictive factor of structural progression of medial tibiofemoral knee osteoarthritis — results of a 1 year longitudinal arthroscopic study in 422 patients. Osteoarthritis Cartilage 13, 361–367 (2005). · DOI
  29. Sokolove, J. & Lepus, C. M. Role of inflammation in the pathogenesis of osteoarthritis: latest findings and interpretations. Ther. Adv. Musculoskeletal Dis. 5, 77–94 (2013). · DOI · Paper page
  30. Benito, M. J., Veale, D. J., FitzGerald, O., van den Berg, W. B. & Bresnihan, B. Synovial tissue inflammation in early and late osteoarthritis. Ann. Rheum. Dis. 64, 1263–1267 (2005). · DOI
  31. Chevalier, X., Eymard, F. & Richette, P. Biologic agents in osteoarthritis: hopes and disappointments. Nat. Rev. Rheumatol. 9, 400–410 (2013). · DOI
  32. Glasson, S. S. In vivo osteoarthritis target validation utilizing genetically-modified mice. Curr. Drug Targets 8, 367–376 (2007). · DOI
  33. van Lent, P. L. et al. Crucial role of synovial lining macrophages in the promotion of transforming growth factor β-mediated osteophyte formation. Arthritis Rheum. 50, 103–111 (2004). · DOI
  34. You, T. & Nicklas, B. J. Chronic inflammation: role of adipose tissue and modulation by weight loss. Curr. Diabetes Rev. 2, 29–37 (2006). · DOI
  35. Beavers, K. M. et al. Effects of total and regional fat loss on plasma CRP and IL-6 in overweight and obese, older adults with knee osteoarthritis. Osteoarthritis Cartilage 23, 249–256 (2015). · DOI
  36. Vincent, H. K., Heywood, K., Connelly, J. & Hurley, R. W. Obesity and weight loss in the treatment and prevention of osteoarthritis. PM R. 4 (5 Suppl.), S59–S67 (2012). · DOI
  37. Haseeb, A. & Haqqi, T. M. Immunopathogenesis of osteoarthritis. Clin. Immunol. 146, 185–196 (2013). · DOI
  38. Scanzello, C. R., Plaas, A. & Crow, M. K. Innate immune system activation in osteoarthritis: is osteoarthritis a chronic wound? Current opinion in rheumatology 20, 565–572 (2008). · DOI
  39. Krenn, V. et al. Grading of chronic synovitis — a histopathological grading system for molecular and diagnostic pathology. Pathol. Res. Pract. 198, 317–325 (2002). · DOI
  40. Slansky, E. et al. Quantitative determination of the diagnostic accuracy of the synovitis score and its components. Histopathology 57, 436–443 (2010). · DOI
  41. de Lange-Brokaar, B. J. et al. Synovial inflammation, immune cells and their cytokines in osteoarthritis: a review. Osteoarthritis Cartilage 20, 1484–1499 (2012). · DOI
  42. Cohen, S. B. et al. A randomized, double-blind study of AMG 108 (a fully human monoclonal antibody to IL-1R1) in patients with osteoarthritis of the knee. Arthritis Res. Ther. 13, R125 (2011). · DOI
  43. Magnano, M. D. et al. A pilot study of tumor necrosis factor inhibition in erosive/inflammatory osteoarthritis of the hands. J. Rheumatol. 34, 1323–1327 (2007).
  44. Verbruggen, G., Wittoek, R., Vander Cruyssen, B. & Elewaut, D. Tumour necrosis factor blockade for the treatment of erosive osteoarthritis of the interphalangeal finger joints: a double blind, randomised trial on structure modification. Ann. Rheum. Dis. 71, 891–898 (2012). · DOI
  45. Chevalier, X. et al. Intraarticular injection of anakinra in osteoarthritis of the knee: a multicenter, randomized, double-blind, placebo-controlled study. Arthritis Rheum. 61, 344–352 (2009). · DOI
  46. Orlowsky, E. W. & Kraus, V. B. The role of innate immunity in osteoarthritis: when our first line of defense goes on the offensive. J. Rheumatol. 42, 363–371 (2015). · DOI
  47. Fearon, D. T. & Locksley, R. M. The instructive role of innate immunity in the acquired immune response. Science 272, 50–53 (1996). · DOI
  48. Holers, V. M. & Thurman, J. M. The alternative pathway of complement in disease: opportunities for therapeutic targeting. Mol. Immunol. 41, 147–152 (2004). · DOI
  49. Wang, Q. et al. Identification of a central role for complement in osteoarthritis. Nat. Med. 17, 1674–1679 (2011). · DOI
  50. Rus, H., Cudrici, C. & Niculescu, F. The role of the complement system in innate immunity. Immunol. Res. 33, 103–112 (2005). · DOI
  51. Song, W. C., Sarrias, M. R. & Lambris, J. D. Complement and innate immunity. Immunopharmacology 49, 187–198 (2000). · DOI
  52. Happonen, K. E. et al. Regulation of complement by COMP allows for a novel molecular diagnostic principle in rheumatoid arthritis. Arthritis Rheum. 62, 3574–3783 (2010). · DOI
  53. Sjoberg, A. P. et al. Short leucine-rich glycoproteins of the extracellular matrix display diverse patterns of complement interaction and activation. Mol. Immunol. 46, 830–839 (2009). · DOI
  54. Sjoberg, A., Onnerfjord, P., Morgelin, M., Heinegard, D. & Blom, A. M. The extracellular matrix and inflammation: fibromodulin activates the classical pathway of complement by directly binding C1q. J. Biol. Chem. 280, 32301–32308 (2005). · DOI
  55. Moreth, K., Iozzo, R. V. & Schaefer, L. Small leucine-rich proteoglycans orchestrate receptor crosstalk during inflammation. Cell Cycle 11, 2084–2091 (2012). · DOI
  56. Rosenthal, A. K. Crystals, inflammation, and osteoarthritis. Curr. Opin. Rheumatol. 23, 170–173 (2011). · DOI
  57. Sofat, N. Analysing the role of endogenous matrix molecules in the development of osteoarthritis. Int. J. Exp. Pathol. 90, 463–479 (2009). · DOI
  58. Nasi, S. et al. Dispensable role of myeloid differentiation primary response gene 88 (MyD88) and MyD88-dependent Toll-like receptors (TLRs) in a murine model of osteoarthritis. Joint Bone Spine 81, 320–324 (2014). · DOI
  59. Liu-Bryan, R. Synovium and the innate inflammatory network in osteoarthritis progression. Curr. Rheumatol. Rep. 15, 323 (2013). · DOI
  60. Rosado, C. J. et al. A common fold mediates vertebrate defense and bacterial attack. Science 317, 1548–1551 (2007). · DOI
  61. Tschopp, J., Masson, D. & Stanley, K. K. Structural/functional similarity between proteins involved in complement- and cytotoxic T-lymphocyte-mediated cytolysis. Nature 322, 831–834 (1986). · DOI
  62. Bohana-Kashtan, O., Ziporen, L., Donin, N., Kraus, S. & Fishelson, Z. Cell signals transduced by complement. Mol. Immunol. 41, 583–597 (2004). · DOI
  63. Cooke, T. D., Bennett, E. L. & Ohno, O. The deposition of immunoglobulins and complement in osteoarthritic cartilage. Int. Orthop. 4, 211–217 (1980). · DOI
  64. Corvetta, A. et al. Terminal complement complex in synovial tissue from patients affected by rheumatoid arthritis, osteoarthritis and acute joint trauma. Clin. Exp. Rheumatol. 10, 433–438 (1992).
  65. Bradley, K. et al. Synthesis of classical pathway complement components by chondrocytes. Immunology 88, 648–656 (1996).
  66. Kemper, C. & Atkinson, J. P. T-Cell regulation: with complements from innate immunity. Nat. Rev. Immunol. 7, 9–18 (2007). · DOI
  67. Lepus, C. M. et al. Brief report: carboxypeptidase B serves as a protective mediator in osteoarthritis. Arthritis Rheumatol. 66, 101–106 (2014). · DOI
  68. Boffa, M. C., Burke, B. & Haudenschild, C. C. Preservation of thrombomodulin antigen on vascular and extravascular surfaces. J. Histochem. Cytochem. 35, 1267–1276 (1987). · DOI
  69. McCachren, S. S., Diggs, J., Weinberg, J. B. & Dittman, W. A. Thrombomodulin expression by human blood monocytes and by human synovial tissue lining macrophages. Blood 78, 3128–3132 (1991). · DOI
  70. Conway, E. M., Nowakowski, B. & Steiner-Mosonyi, M. Human neutrophils synthesize thrombomodulin that does not promote thrombin-dependent protein C activation. Blood 80, 1254–1263 (1992). · DOI
  71. Leung, L. L., Myles, T., Nishimura, T., Song, J. J. & Robinson, W. H. Regulation of tissue inflammation by thrombin-activatable carboxypeptidase B (or TAFI). Mol. Immunol. 45, 4080–4083 (2008). · DOI
  72. Sharif, S. A. et al. Thrombin-activatable carboxypeptidase B cleavage of osteopontin regulates neutrophil survival and synoviocyte binding in rheumatoid arthritis. Arthritis Rheum. 60, 2902–2912 (2009). · DOI
  73. Benoit, M. E., Clarke, E. V., Morgado, P., Fraser, D. A. & Tenner, A. J. Complement protein C1q directs macrophage polarization and limits inflammasome activity during the uptake of apoptotic cells. J. Immunol. 188, 5682–5693 (2012). · DOI
  74. Foell, D., Wittkowski, H. & Roth, J. Mechanisms of disease: a 'DAMP' view of inflammatory arthritis. Nat. Clin. Pract. Rheumatol. 3, 382–390 (2007). · DOI
  75. Blom, A. B. et al. Crucial role of macrophages in matrix metalloproteinase-mediated cartilage destruction during experimental osteoarthritis: involvement of matrix metalloproteinase 3. Arthritis Rheum. 56, 147–157 (2007). · DOI
  76. Bondeson, J. Activated synovial macrophages as targets for osteoarthritis drug therapy. Curr. Drug Targets 11, 576–585 (2010). · DOI
  77. Irani, A. A., Schechter, N. M., Craig, S. S., DeBlois, G. & Schwartz, L. B. Two types of human mast cells that have distinct neutral protease compositions. Proc. Natl Acad. Sci. USA 83, 4464–4468 (1986). · DOI
  78. Buckley, M. G., Gallagher, P. J. & Walls, A. F. Mast cell subpopulations in the synovial tissue of patients with osteoarthritis: selective increase in numbers of tryptase-positive, chymase-negative mast cells. J. Pathol. 186, 67–74 (1998). · DOI
  79. Gotis-Graham, I. & McNeil, H. P. Mast cell responses in rheumatoid synovium. Association of the MCTC subset with matrix turnover and clinical progression. Arthritis Rheum. 40, 479–489 (1997). · DOI
  80. Nakano, S. et al. Distinct expression of mast cell tryptase and protease activated receptor-2 in synovia of rheumatoid arthritis and osteoarthritis. Clin. Rheumatol. 26, 1284–1292 (2007). · DOI
  81. Bridges, A. J. et al. Human synovial mast cell involvement in rheumatoid arthritis and osteoarthritis. Relationship to disease type, clinical activity, and antirheumatic therapy. Arthritis Rheum. 34, 1116–1124 (1991). · DOI
  82. Gruber, B. et al. Characterization and functional studies of rheumatoid synovial mast cells. Activation by secretagogues, anti-IgE, and a histamine-releasing lymphokine. Arthritis Rheum. 29, 944–955 (1986). · DOI
  83. Kopicky-Burd, J. A. et al. Characterization of human synovial mast cells. J. Rheumatol. 15, 1326–1333 (1988).
  84. Cooke, T. D. Significance of immune complex deposits in osteoarthritic cartilage. J. Rheumatol. 14, 77–79 (1987).
  85. Vargas, M. E., Watanabe, J., Singh, S. J., Robinson, W. H. & Barres, B. A. Endogenous antibodies promote rapid myelin clearance and effective axon regeneration after nerve injury. Proc. Natl Acad. Sci. USA 107, 11993–11998 (2010). · DOI
  86. Goldring, M. B., Fukuo, K., Birkhead, J. R., Dudek, E. & Sandell, L. J. Transcriptional suppression by interleukin-1 and interferon-γ of type II collagen gene expression in human chondrocytes. J. Cell Biochem. 54, 85–99 (1994). · DOI
  87. Saklatvala, J. Tumour necrosis factor α stimulates resorption and inhibits synthesis of proteoglycan in cartilage. Nature 322, 547–549 (1986). · DOI
  88. Attur, M. G., Patel, I. R., Patel, R. N., Abramson, S. B. & Amin, A. R. Autocrine production of IL-1β by human osteoarthritis-affected cartilage and differential regulation of endogenous nitric oxide, IL-6, prostaglandin E2, and IL-8. Proc. Assoc. Am. Physicians 110, 65–72 (1998).
  89. Krzeski, P. et al. Development of musculoskeletal toxicity without clear benefit after administration of PG-116800, a matrix metalloproteinase inhibitor, to patients with knee osteoarthritis: a randomized, 12-month, double-blind, placebo-controlled study. Arthritis Res. Ther. 9, R109 (2007). · DOI
  90. Catterall, J. B. & Cawston, T. E. Drugs in development: bisphosphonates and metalloproteinase inhibitors. Arthritis Res. Ther. 5, 12–24 (2003). · DOI
  91. Clutterbuck, A. L., Asplin, K. E., Harris, P., Allaway, D. & Mobasheri, A. Targeting matrix metalloproteinases in inflammatory conditions. Curr. Drug Targets 10, 1245–1254 (2009). · DOI
  92. Endres, M. et al. Chemokine profile of synovial fluid from normal, osteoarthritis and rheumatoid arthritis patients: CCL25, CXCL10 and XCL1 recruit human subchondral mesenchymal progenitor cells. Osteoarthritis Cartilage 18, 1458–1466 (2010). · DOI
  93. Haringman, J. J., Smeets, T. J., Reinders-Blankert, P. & Tak, P. P. Chemokine and chemokine receptor expression in paired peripheral blood mononuclear cells and synovial tissue of patients with rheumatoid arthritis, osteoarthritis, and reactive arthritis. Ann. Rheum. Dis. 65, 294–300 (2006). · DOI
  94. Borzi, R. M. et al. Human chondrocytes express functional chemokine receptors and release matrix-degrading enzymes in response to C-X-C and C-C chemokines. Arthritis Rheum. 43, 1734–1741 (2000). · DOI
  95. Miller, R. J., Banisadr, G. & Bhattacharyya, B. J. CXCR4 signaling in the regulation of stem cell migration and development. J. Neuroimmunol. 198, 31–38 (2008). · DOI
  96. Haringman, J. J., Ludikhuize, J. & Tak, P. P. Chemokines in joint disease: the key to inflammation? Ann. Rheum. Dis. 63, 1186–1194 (2004). · DOI
  97. Shen, J., Li, S. & Chen, D. TGF-β signaling and the development of osteoarthritis. Bone Res. 2, 14002 (2014). · DOI
  98. Blaney Davidson, E. N., van der Kraan, P. M. & van den Berg, W. B. TGF-β and osteoarthritis. Osteoarthritis Cartilage 15, 597–604 (2007). · DOI
  99. Ellman, M. B. et al. Fibroblast growth factor control of cartilage homeostasis. J. Cell Biochem. 114, 735–742 (2013). · DOI
  100. Haywood, L. et al. Inflammation and angiogenesis in osteoarthritis. Arthritis Rheum. 48, 2173–2177 (2003). · DOI
  101. Prencipe, G. et al. Nerve growth factor downregulates inflammatory response in human monocytes through TrkA. J. Immunol. 192, 3345–3354 (2014). · DOI
  102. Lane, N. E. et al. Tanezumab for the treatment of pain from osteoarthritis of the knee. N. Engl. J. Med. 363, 1521–1531 (2010). · DOI
  103. Thysen, S., Luyten, F. P. & Lories, R. J. Targets, models and challenges in osteoarthritis research. Dis. Model. Mech. 8, 17–30 (2015). · DOI
  104. Henrotin, Y., Pesesse, L. & Lambert, C. Targeting the synovial angiogenesis as a novel treatment approach to osteoarthritis. Ther. Adv. Musculoskeletal Dis. 6, 20–34 (2014). · DOI
  105. de Boer, T. N. et al. Serum adipokines in osteoarthritis; comparison with controls and relationship with local parameters of synovial inflammation and cartilage damage. Osteoarthritis Cartilage 20, 846–853 (2012). · DOI
  106. Kluzek, S., Newton, J. L. & Arden, N. K. Is osteoarthritis a metabolic disorder? Br. Med. Bull. 115, 111–121 (2015). · DOI
  107. Malemud, C. J. Biologic basis of osteoarthritis: state of the evidence. Curr. Opin. Rheumatol. 27, 289–294 (2015). · DOI
  108. Yusuf, E. et al. Association between weight or body mass index and hand osteoarthritis: a systematic review. Ann. Rheum. Dis. 69, 761–765 (2010). · DOI
  109. Le Clanche, S., Bonnefont-Rousselot, D., Sari-Ali, E., Rannou, F. & Borderie, D. Inter-relations between osteoarthritis and metabolic syndrome: a common link? Biochimie 121, 238–252 (2016). · DOI
  110. Conde, J. et al. Adipokines and osteoarthritis: novel molecules involved in the pathogenesis and progression of disease. Arthritis 2011, 203901 (2011). · DOI
  111. Gomez, R. et al. What's new in our understanding of the role of adipokines in rheumatic diseases? Nat. Rev. Rheumatol. 7, 528–536 (2011). · DOI
  112. Dumond, H. et al. Evidence for a key role of leptin in osteoarthritis. Arthritis Rheum. 48, 3118–3129 (2003). · DOI
  113. Filkova, M. et al. Increased serum adiponectin levels in female patients with erosive compared with non-erosive osteoarthritis. Ann. Rheum. Dis. 68, 295–296 (2009). · DOI
  114. Francin, P. J. et al. Association between adiponectin and cartilage degradation in human osteoarthritis. Osteoarthritis Cartilage 22, 519–526 (2014). · DOI
  115. Liao, L., Chen, Y. & Wang, W. The current progress in understanding the molecular functions and mechanisms of visfatin in osteoarthritis. J. Bone Miner. Metab. http://dx.doi.org/10.1007/s00774-016-0743-1 (2016). · DOI
  116. Koskinen, A., Vuolteenaho, K., Moilanen, T. & Moilanen, E. Resistin as a factor in osteoarthritis: synovial fluid resistin concentrations correlate positively with interleukin 6 and matrix metalloproteinases MMP-1 and MMP-3. Scand. J. Rheumatol. 43, 249–253 (2014). · DOI
  117. Jiang, L., Bao, J., Zhou, X., Xiong, Y. & Wu, L. Increased serum levels and chondrocyte expression of nesfatin-1 in patients with osteoarthritis and its relation with BMI, hsCRP, and IL-18. Mediators Inflamm. 2013, 631251 (2013).
  118. Yang, S. et al. NAMPT (visfatin), a direct target of hypoxia-inducible factor-2α, is an essential catabolic regulator of osteoarthritis. Ann. Rheum. Dis. 74, 595–602 (2015). · DOI
  119. Gegout, P. P., Francin, P. J., Mainard, D. & Presle, N. Adipokines in osteoarthritis: friends or foes of cartilage homeostasis? Joint Bone Spine 75, 669–671 (2008). · DOI
  120. Presle, N. et al. Differential distribution of adipokines between serum and synovial fluid in patients with osteoarthritis. Contribution of joint tissues to their articular production. Osteoarthritis Cartilage 14, 690–695 (2006). · DOI
  121. Martel-Pelletier, J., Pelletier, J. P. & Fahmi, H. Cyclooxygenase-2 and prostaglandins in articular tissues. Semin. Arthritis Rheum. 33, 155–167 (2003). · DOI
  122. Wittenberg, R. H., Willburger, R. E., Kleemeyer, K. S. & Peskar, B. A. In vitro release of prostaglandins and leukotrienes from synovial tissue, cartilage, and bone in degenerative joint diseases. Arthritis Rheum. 36, 1444–1450 (1993). · DOI
  123. Casale, T. B., Abbas, M. K. & Carolan, E. J. Degree of neutrophil chemotaxis is dependent upon the chemoattractant and barrier. Am. J. Respir. Cell. Mol. Biol. 7, 112–117 (1992). · DOI
  124. He, W., Pelletier, J. P., Martel-Pelletier, J., Laufer, S. & Di Battista, J. A. Synthesis of interleukin 1β, tumor necrosis factor-α, and interstitial collagenase (MMP-1) is eicosanoid dependent in human osteoarthritis synovial membrane explants: interactions with antiinflammatory cytokines. J. Rheumatol. 29, 546–553 (2002).
  125. Peters-Golden, M. & Henderson, W. R. Jr. Leukotrienes. N. Engl. J. Med. 357, 1841–1854 (2007). · DOI
  126. Geng, Y., Blanco, F. J., Cornelisson, M. & Lotz, M. Regulation of cyclooxygenase-2 expression in normal human articular chondrocytes. J. Immunol. 155, 796–801 (1995). · DOI
  127. Li, X. et al. Expression and regulation of microsomal prostaglandin E synthase-1 in human osteoarthritic cartilage and chondrocytes. J. Rheumatol. 32, 887–895 (2005).
  128. Masuko-Hongo, K. et al. Up-regulation of microsomal prostaglandin E synthase 1 in osteoarthritic human cartilage: critical roles of the ERK-1/2 and p38 signaling pathways. Arthritis Rheum. 50, 2829–2838 (2004). · DOI
  129. Kojima, F. et al. Membrane-associated prostaglandin E synthase-1 is upregulated by proinflammatory cytokines in chondrocytes from patients with osteoarthritis. Arthritis Res. Ther. 6, R355–R365 (2004). · DOI
  130. Paredes, Y. et al. Study of the role of leukotriene B4 in abnormal function of human subchondral osteoarthritis osteoblasts: effects of cyclooxygenase and/or 5-lipoxygenase inhibition. Arthritis Rheum. 46, 1804–1812 (2002). · DOI
  131. Scarpignato, C. et al. Safe prescribing of non-steroidal anti-inflammatory drugs in patients with osteoarthritis — an expert consensus addressing benefits as well as gastrointestinal and cardiovascular risks. BMC Med. 13, 55 (2015). · DOI
  132. Steinhilber, D. & Hofmann, B. Recent advances in the search for novel 5-lipoxygenase inhibitors. Bas. Clin. Pharmacol. Toxicol. 114, 70–77 (2014). · DOI
  133. Tonge, D. P., Pearson, M. J. & Jones, S. W. The hallmarks of osteoarthritis and the potential to develop personalised disease-modifying pharmacological therapeutics. Osteoarthritis Cartilage 22, 609–621 (2014). · DOI
  134. Abramson, S. B. Osteoarthritis and nitric oxide. Osteoarthritis Cartilage 16 (Suppl. 2), S15–S20 (2008). · DOI
  135. Palmer, R. M., Hickery, M. S., Charles, I. G., Moncada, S. & Bayliss, M. T. Induction of nitric oxide synthase in human chondrocytes. Biochem. Biophys. Res. Commun. 193, 398–405 (1993). · DOI
  136. McInnes, I. B. et al. Production of nitric oxide in the synovial membrane of rheumatoid and osteoarthritis patients. J. Exp. Med. 184, 1519–1524 (1996). · DOI
  137. Farrell, A. J., Blake, D. R., Palmer, R. M. & Moncada, S. Increased concentrations of nitrite in synovial fluid and serum samples suggest increased nitric oxide synthesis in rheumatic diseases. Ann. Rheum. Dis. 51, 1219–1222 (1992). · DOI
  138. Hashimoto, S., Takahashi, K., Amiel, D., Coutts, R. D. & Lotz, M. Chondrocyte apoptosis and nitric oxide production during experimentally induced osteoarthritis. Arthritis Rheum. 41, 1266–1274, http://dx.doi.org/10.1002/1529-0131 (199807)41:7<1266::AID-ART18>3.0.CO;2-Y (1998). · DOI
  139. Notoya, K. et al. The induction of cell death in human osteoarthritis chondrocytes by nitric oxide is related to the production of prostaglandin E2 via the induction of cyclooxygenase-2. J. Immunol. 165, 3402–3410 (2000). · DOI
  140. Scher, J. U., Pillinger, M. H. & Abramson, S. B. Nitric oxide synthases and osteoarthritis. Curr. Rheumatol. Rep. 9, 9–15 (2007). · DOI
  141. Hellio le Graverand, M. P. et al. A 2-year randomised, double-blind, placebo-controlled, multicentre study of oral selective iNOS inhibitor, cindunistat (SD-6010), in patients with symptomatic osteoarthritis of the knee. Ann. Rheum. Dis. 72, 187–195 (2013). · DOI
  142. Sutton, S. et al. The contribution of the synovium, synovial derived inflammatory cytokines and neuropeptides to the pathogenesis of osteoarthritis. Vet. J. 179, 10–24 (2009). · DOI
  143. Meini, S. & Maggi, C. A. Knee osteoarthritis: a role for bradykinin? Inflamm. Res. 57, 351–361 (2008). · DOI
  144. Song, I. H. et al. Contrast-enhanced ultrasound in monitoring the efficacy of a bradykinin receptor 2 antagonist in painful knee osteoarthritis compared with MRI. Ann. Rheum. Dis. 68, 75–83 (2009). · DOI
  145. Dudek, M. et al. The chondrocyte clock gene Bmal1 controls cartilage homeostasis and integrity. J. Clin. Invest. 126, 365–376 (2016). · DOI
  146. Kc, R. et al. Environmental disruption of circadian rhythm predisposes mice to osteoarthritis-like changes in knee joint. J. Cell. Physiol. 230, 2174–2183 (2015). · DOI
  147. Gossan, N. et al. The circadian clock in murine chondrocytes regulates genes controlling key aspects of cartilage homeostasis. Arthritis Rheum. 65, 2334–2345 (2013). · DOI
  148. Guo, B. et al. Catabolic cytokines disrupt the circadian clock and the expression of clock-controlled genes in cartilage via an NFκB-dependent pathway. Osteoarthritis Cartilage 23, 1981–1988 (2015). · DOI
  149. Honda, K. K. et al. Different circadian expression of major matrix-related genes in various types of cartilage: modulation by light-dark conditions. J. Biochem. 154, 373–381 (2013). · DOI
  150. Takarada, T. et al. Clock genes influence gene expression in growth plate and endochondral ossification in mice. J. Biol. Chem. 287, 36081–36095 (2012). · DOI
  151. Gibbs, J. et al. An epithelial circadian clock controls pulmonary inflammation and glucocorticoid action. Nat. Med. 20, 919–926 (2014). · DOI
  152. Nguyen, K. D. et al. Circadian gene Bmal1 regulates diurnal oscillations of Ly6Chi inflammatory monocytes. Science 341, 1483–1488 (2013). · DOI
  153. Gibbs, J. E. et al. The nuclear receptor REV-ERBα mediates circadian regulation of innate immunity through selective regulation of inflammatory cytokines. Proc. Natl Acad. Sci. USA 109, 582–587 (2012). · DOI
  154. Mobasheri, A. The future of osteoarthritis therapeutics: targeted pharmacological therapy. Curr. Rheumatol. Rep. 15, 364 (2013). · DOI
  155. Mobasheri, A. The future of osteoarthritis therapeutics: emerging biological therapy. Curr. Rheumatol. Rep. 15, 385 (2013). · DOI
  156. Hunter, D. J. Are there promising biologic therapies for osteoarthritis? Curr. Rheumatol. Rep. 10, 19–25 (2008). · DOI
  157. Pelletier, J. P. et al. Disease-modifying effect of strontium ranelate in a subset of patients from the Phase III knee osteoarthritis study SEKOIA using quantitative MRI: reduction in bone marrow lesions protects against cartilage loss. Ann. Rheum. Dis. 74, 422–429 (2015). · DOI
  158. Reginster, J. Y. et al. Efficacy and safety of strontium ranelate in the treatment of knee osteoarthritis: results of a double-blind, randomised placebo-controlled trial. Ann. Rheum. Dis. 72, 179–186 (2013). · DOI
  159. Pelletier, J. P. et al. Strontium ranelate reduces the progression of experimental dog osteoarthritis by inhibiting the expression of key proteases in cartilage and of IL-1β in the synovium. Ann. Rheum. Dis. 72, 250–257 (2013). · DOI
  160. Tat, S. K., Pelletier, J. P., Mineau, F., Caron, J. & Martel-Pelletier, J. Strontium ranelate inhibits key factors affecting bone remodeling in human osteoarthritic subchondral bone osteoblasts. Bone 49, 559–567 (2011). · DOI
  161. Lafeber, F. P. & van Laar, J. M. Strontium ranelate: ready for clinical use as disease-modifying osteoarthritis drug? Ann. Rheum. Dis. 72, 157–161 (2013). · DOI
  162. Felson, D. T. Developments in the clinical understanding of osteoarthritis. Arthritis Res. Ther. 11, 203 (2009). · DOI
  163. Midwood, K. et al. Tenascin-C is an endogenous activator of Toll-like receptor 4 that is essential for maintaining inflammation in arthritic joint disease. Nat. Med. 15, 774–780 (2009). · DOI
  164. van Lent, P. L. et al. Active involvement of alarmins S100A8 and S100A9 in the regulation of synovial activation and joint destruction during mouse and human osteoarthritis. Arthritis Rheum. 64, 1466–1476 (2012). · DOI
  165. Schelbergen, R. F. et al. Alarmins S100A8/S100A9 aggravate osteophyte formation in experimental osteoarthritis and predict osteophyte progression in early human symptomatic osteoarthritis. Ann. Rheum. Dis. 75, 218–225 (2016). · DOI
  166. Joosten, L. A., Helsen, M. M., van de Loo, F. A. & van den Berg, W. B. Anticytokine treatment of established type II collagen-induced arthritis in DBA/1 mice: a comparative study using anti-TNFα, anti-IL-1α/β and IL-1Ra. Arthritis Rheum. 58, S110–122 (2008). · DOI
  167. Rudolphi, K., Gerwin, N., Verzijl, N., van der Kraan, P. & van den Berg, W. Pralnacasan, an inhibitor of interleukin-1β converting enzyme, reduces joint damage in two murine models of osteoarthritis. Osteoarthritis Cartilage 11, 738–746 (2003). · DOI
  168. Zhang, Q., Lv, H., Chen, A., Liu, F. & Wu, X. Efficacy of infliximab in a rabbit model of osteoarthritis. Connect. Tissue Res. 53, 355–358 (2012). · DOI
  169. Urech, D. M. et al. Anti-inflammatory and cartilage-protecting effects of an intra-articularly injected anti-TNFα single-chain Fv antibody (ESBA105) designed for local therapeutic use. Ann. Rheum. Dis. 69, 443–449 (2010). · DOI
  170. Koewler, N. J. et al. Effects of a monoclonal antibody raised against nerve growth factor on skeletal pain and bone healing after fracture of the C57BL/6J mouse femur. J. Bone Miner. Res. 22, 1732–1742 (2007). · DOI
  171. Moore, E. E. et al. Fibroblast growth factor-18 stimulates chondrogenesis and cartilage repair in a rat model of injury-induced osteoarthritis. Osteoarthritis Cartilage 13, 623–631 (2005). · DOI
  172. Evans, C. H., Kraus, V. B. & Setton, L. A. Progress in intra-articular therapy. Nat. Rev. Rheumatol. 10, 11–22 (2014). · DOI
  173. Ou, Y. et al. Selective COX-2 inhibitor ameliorates osteoarthritis by repressing apoptosis of chondrocyte. Med. Sci. Monit. 18, 247–252 (2012). · DOI
  174. Drazen, J. M. COX-2 inhibitors — a lesson in unexpected problems. N. Engl. J. Med. 352, 1131–1132 (2005). · DOI
  175. Nussmeier, N. A. et al. Complications of the COX-2 inhibitors parecoxib and valdecoxib after cardiac surgery. N. Engl. J. Med. 352, 1081–1091 (2005). · DOI
  176. Solomon, S. D. et al. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N. Engl. J. Med. 352, 1071–1080 (2005). · DOI
  177. Riendeau, D. et al. Etoricoxib (MK-0663): preclinical profile and comparison with other agents that selectively inhibit cyclooxygenase-2. J. Pharmacol. Exp. Ther. 296, 558–566 (2001). · DOI
  178. Song, G. G. et al. Relative efficacy and tolerability of etoricoxib, celecoxib, and naproxen in the treatment of osteoarthritis: a Bayesian network meta-analysis of randomized controlled trials based on patient withdrawal. Z. Rheumatol. 75, 508–516 (2016). · DOI
  179. Croom, K. F. & Siddiqui, M. A. Etoricoxib: a review of its use in the symptomatic treatment of osteoarthritis, rheumatoid arthritis, ankylosing spondylitis and acute gouty arthritis. Drugs 69, 1513–1532 (2009). · DOI
  180. Ratcliffe, A. et al. The in vivo effects of naproxen on canine experimental osteoarthritic articular cartilage: composition, metalloproteinase activities and metabolism. Agents Actions Suppl. 39, 207–211 (1993). · DOI
  181. Svensson, O., Malmenas, M., Fajutrao, L., Roos, E. M. & Lohmander, L. S. Greater reduction of knee than hip pain in osteoarthritis treated with naproxen, as evaluated by WOMAC and SF-36. Ann. Rheum. Dis. 65, 781–784 (2006). · DOI
  182. Coxib and traditional NSAID Trialists' (CNT) Collaboration et al. Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials. Lancet 382, 769–779 (2013). · DOI
  183. Masferrer, J. L. et al. Pharmacology of PF-4191834, a novel, selective non-redox 5-lipoxygenase inhibitor effective in inflammation and pain. J. Pharmacol. Exp. Ther. 334, 294–301 (2010). · DOI
  184. Jovanovic, D. V. et al. In vivo dual inhibition of cyclooxygenase and lipoxygenase by ML-3000 reduces the progression of experimental osteoarthritis: suppression of collagenase 1 and interleukin-1β synthesis. Arthritis Rheum. 44, 2320–2330 (2001). · DOI
  185. Raynauld, J. P. et al. Protective effects of licofelone, a 5-lipoxygenase and cyclo-oxygenase inhibitor, versus naproxen on cartilage loss in knee osteoarthritis: a first multicentre clinical trial using quantitative MRI. Ann. Rheum. Dis. 68, 938–947 (2009). · DOI
  186. Bitto, A. et al. Flavocoxid, a nutraceutical approach to blunt inflammatory conditions. Mediators Inflamm. 2014, 790851 (2014). · DOI
  187. Levy, R. M. et al. Efficacy and safety of flavocoxid, a novel therapeutic, compared with naproxen: a randomized multicenter controlled trial in subjects with osteoarthritis of the knee. Adv. Ther. 27, 731–742 (2010). · DOI
  188. Chalasani, N. et al. Acute liver injury due to flavocoxid (Limbrel), a medical food for osteoarthritis: a case series. Ann. Intern. Med. 156, 857–860 (2012). · DOI
  189. Stefanovic-Racic, M. et al. N-Monomethyl arginine, an inhibitor of nitric oxide synthase, suppresses the development of adjuvant arthritis in rats. Arthritis Rheum. 37, 1062–1069 (1994). · DOI
  190. McCartney-Francis, N. et al. Suppression of arthritis by an inhibitor of nitric oxide synthase. J. Exp. Med. 178, 749–754 (1993). · DOI
  191. Miyasaka, N. & Hirata, Y. Nitric oxide and inflammatory arthritides. Life Sci. 61, 2073–2081 (1997). · DOI · Paper page
  192. More, A. S. et al. Effect of iNOS inhibitor S-methylisothiourea in monosodium iodoacetate-induced osteoathritic pain: implication for osteoarthritis therapy. Pharmacol. Biochem. Behav. 103, 764–772 (2013). · DOI
  193. Brewster, M., Lewis, E. J., Wilson, K. L., Greenham, A. K. & Bottomley, K. M. Ro 32–3555, an orally active collagenase selective inhibitor, prevents structural damage in the STR/ORT mouse model of osteoarthritis. Arthritis Rheum. 41, 1639–1644 (1998). · DOI
  194. Close, D. R. Matrix metalloproteinase inhibitors in rheumatic diseases. Ann. Rheum. Dis. 60 (Suppl. 3), 62–67 (2001). · DOI
  195. Fujisawa, T. et al. Highly water-soluble matrix metalloproteinases inhibitors and their effects in a rat adjuvant-induced arthritis model. Bioorg. Med. Chem. 10, 2569–2581 (2002). · DOI
  196. Janusz, M. J. et al. Moderation of iodoacetate-induced experimental osteoarthritis in rats by matrix metalloproteinase inhibitors. Osteoarthritis Cartilage 9, 751–760 (2001). · DOI
  197. Lewis, E. J. et al. Ro 32–3555, an orally active collagenase inhibitor, prevents cartilage breakdown in vitro and in vivo. Br. J. Pharmacol. 121, 540–546 (1997). · DOI

Cited by

Metadata

Authors
Robinson, W. H., Lepus, C. M., Wang, Q., Raghu, H., Mao, R., Lindstrom, T. M., & Sokolove, J.
Venue
Nature Reviews Rheumatology
Publisher
Springer Science and Business Media LLC
Published
2016-08-19
Volume
12
Issue
10
Pages
580-592
ISSN
  • 1759-4790
  • 1759-4804
DOI
10.1038/nrrheum.2016.136
PMC
PMC5500215
Cited by
1,438
References
7
Language
en
Licence
www.springer.com/tdm (tdm)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review